Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ChemGenex Pharmaceuticals
Australia
- Ownership
- Private
- Development stage
- Other
01
Overview
ChemGenex developed targeted oncology drugs, most notably omacetaxine mepesuccinate ("Omapro") for drug-resistant CML. The company's pivotal trial faced regulatory challenges regarding diagnostic testing and efficacy data. Its lead asset's US launch was delayed due to FDA concerns about trial design and patient selection. European rights to Omapro were licensed out in a deal worth up to $136 million. All major development programs have since been discontinued or are pending with no recent activity reported.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesTargeted therapies
- Industry
- Biotech
02
Partnerships
Licensed European/Middle East/Africa rights for Omapro in a deal worth up to $136 million as of late December prior to acquisition.
Beyond the preview
Go deeper on ChemGenex Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChemGenex Pharmaceuticals.